Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/228547

Lähdeviite

Lahtinen , P , Mattila , E , Anttila , V-J , Tillonen , J , Teittinen , M , Nevalainen , P , Salminen , S , Satokari , R & Arkkila , P 2017 , ' Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series ' , World Journal of Gastroenterology , vol. 23 , no. 39 , pp. 7174-7184 . https://doi.org/10.3748/wjg.v23.i39.7174

Julkaisun nimi: Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series
Tekijä: Lahtinen, Perttu; Mattila, Eero; Anttila, Veli-Jukka; Tillonen, Jyrki; Teittinen, Matti; Nevalainen, Pasi; Salminen, Seppo; Satokari, Reetta; Arkkila, Perttu
Tekijän organisaatio: HYKS erva
Department of Medicine
Infektiosairauksien yksikkö
Clinicum
Research Programs Unit
Reetta Maria Satokari / Principal Investigator
Immunobiology Research Program
University of Helsinki
Gastroenterologian yksikkö
HUS Inflammation Center
HUS Abdominal Center
HUS Internal Medicine and Rehabilitation
Päiväys: 2017-10-21
Kieli: eng
Sivumäärä: 11
Kuuluu julkaisusarjaan: World Journal of Gastroenterology
ISSN: 1007-9327
DOI-tunniste: https://doi.org/10.3748/wjg.v23.i39.7174
URI: http://hdl.handle.net/10138/228547
Tiivistelmä: Fecal microbiota transplantation (FMT) is effective in recurrent Clostridium difficile infection (rCDI). Knowledge of the safety and efficacy of FMT treatment in immune deficient patients is scarce. FMT has been suggested as a potential method for an increasing number of new indications besides rCDI. Among our FMT-treated rCDI patients, we reviewed those with major comorbidities: two human immunodeficiency virus patients, six haemodialysis patients, two kidney transplant patients, two liver transplant patients and a patient with chronic lymphatic leukaemia. We also reviewed those treated with FMT for indications other than rCDI: Salmonella carriage (two patients), trimethylaminuria (two patients), small intestinal bacterial overgrowth (SIBO; one patient), and lymphocytic colitis (one patient), as well as a common variable immunodeficiency patient with chronic norovirus infection and ESBL-producing Escherichia coli (E. coli) carriage. Of the thirteen rCDI patients treated with FMT, eleven cleared the CDI. The observed adverse events were not directly attributable to FMT. Concerning the special indications, both Salmonellas and ESBL-producing E. coli were eradicated. One trimethylaminuria patient and one SIBO-patient reported a reduction of symptoms. Three patients did not experience a benefit from FMT: chronic norovirus, lymphocytic colitis and the other fish malodour syndrome. There were no reported side effects in this group. FMT appeared to be safe and effective for immunocompromised patients with rCDI. FMT showed promise for the eradication of antibiotic-resistant bacteria, but further research is warranted.
Avainsanat: Faecal microbiota transplantation
Antibiotic resistance
Clostridium difficile infection
Microbiota
Immunodeficiency
Salmonella infection
ACTIVE ULCERATIVE-COLITIS
CONTROLLED-TRIAL
INFECTION
RECURRENT
CARRIAGE
DISEASE
EFFICACY
THERAPY
UPDATE
GENES
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
WJG_23_7174.pdf 8.020MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot